A genetic breakthrough may soon bring bigger and better tomatoes and eggplants to the world. Scientists have mapped the ...

In a study published in Nature Communications, researchers at the Beijing Institute of Stem Cells and Regeneration (BISCRM) ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

Spread the love Table of Contents Introduction Methodology Top 10 Biotech Giants Rising Stars (11-25) Innovators and ...

The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the demand for gene therapy and genome editing solutions, as these approaches ...

Learn how CASGEVY, the first NHS-approved CRISPR gene therapy, treats sickle cell disease through a revolutionary genetic ...

This study presents an enhanced nuclease prime editor (uPEn) that significantly improves gene knock-in and knockout ...

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...

With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...

Recent research from Duke University has demonstrated a promising new approach that could be used to treat a rare and complex ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...